A drug built to shut down one of mesothelioma’s favorite survival tricks just posted real results in human patients, not mice.
Quick Take
- VT3989, an experimental pill, blocks a cancer growth pathway called YAP/TEAD that mesothelioma tumors depend on to survive.
- A phase 1/2 trial enrolled 172 patients, including 135 with mesothelioma, an aggressive cancer tied to asbestos exposure.
- At optimized doses, 22 mesothelioma patients showed an 86% disease control rate, with seven partial responses and 12 stable cases.
- Side effects stayed mostly mild, and kidney-related proteinuria proved reversible with dose changes.
What The Trial Actually Found
Researchers tested VT3989 in patients whose solid tumors had stopped responding to standard treatment. The trial, reported in Nature Medicine on October 19, 2025, focused heavily on mesothelioma, a rare and deadly cancer usually caused by asbestos exposure. Out of 172 total patients enrolled, 135 had mesothelioma, giving doctors a substantial early look at how the drug performs against this specific disease.
The headline number came from 22 mesothelioma patients treated at what researchers called clinically optimized doses. Among that group, 86% saw their disease controlled, meaning tumors shrank or stopped growing. Seven patients had partial responses, and 12 saw their cancer hold steady instead of spreading, according to reporting from MD Anderson Cancer Center following the European Society for Medical Oncology 2025 conference.
How The Drug Turns Cancer’s Own Signal Against It
Mesothelioma tumors often carry a mutation in a gene called NF2, which normally helps keep cell growth in check. When NF2 breaks down, a protein called YAP runs unchecked, teaming up with a partner called TEAD to keep pushing tumor cells to grow and spread. VT3989 blocks that TEAD partnership directly, cutting off the growth signal the tumor relies on.
MD Anderson researchers described VT3989 as the first drug of its kind to show this effect clearly in mesothelioma patients, rather than just in lab dishes or animal models. The trial specifically enrolled patients whose tumors carried NF2 mutations or had lost a related protein called Merlin, both common features in mesothelioma that make tumors especially dependent on the YAP/TEAD pathway the drug targets.
Safety Numbers Look Manageable So Far
Across the full trial, side effects stayed mostly mild, falling into what doctors call grade 1 or 2, the lowest severity levels tracked in cancer trials. The most notable issue was protein showing up in patients’ urine, a sign doctors watch closely for kidney stress. Researchers say this proteinuria reversed itself once doses were adjusted and did not lead to lasting kidney damage.
Doctors also reported fatigue and swelling in some patients, common complaints in cancer drug trials. Managing the treatment required intermittent dosing schedules and specific thresholds for adjusting doses when urine protein levels rose too high, according to trial materials presented at the European conference. That approach let researchers keep patients on the drug longer while limiting the more serious side effects.
Why Small Numbers Still Matter Here
Mesothelioma has long frustrated oncologists because so few treatments work once the disease returns after initial therapy. Historical response rates for later-line treatments in this cancer tend to run low, which makes a 26% overall response rate among 47 patients at optimized doses stand out as a meaningful improvement, based on the published trial data.
The trial remains ongoing, and researchers themselves describe these results as interim findings from expansion cohorts still enrolling patients. That means durability, how long these responses last, and whether the drug extends survival compared to standard care, still needs more data before doctors can call this treatment established medicine.
What Comes Next For Patients And Researchers
The trial is registered and tracked through ClinicalTrials.gov, giving researchers, doctors, and patients a way to follow enrollment and future results as they come in. A larger, randomized comparison against standard mesothelioma therapy would be the next logical step toward proving this drug’s real-world benefit beyond early-phase enthusiasm.
For a cancer that has offered patients few good options for decades, a treatment that specifically targets the biology driving tumor growth, rather than broadly poisoning cells the way chemotherapy does, represents a genuine shift in approach. These numbers, drawn from a real human trial rather than a lab projection, give mesothelioma patients something they have rarely had: a specific, mechanistic reason for hope.
Scientists are testing a counterintuitive way to fight mesothelioma, an aggressive asbestos-linked cancer with few effective treatments. A new experimental mesothelioma drug kills cancer cells by disabling PRX3, an antioxidant defense that tumors use to suhttps://t.co/qT8lJRjaAn
— Michael W. Deem (@Michael_W_Deem) September 17, 2026
Sources:
sciencedaily.com, cancernetwork.com, delta.larvol.com, mesowatch.org
